What's the Safest Path to Neoadjuvant Therapy in Liver Cancer?

(MedPage Today) -- Immune checkpoint inhibitors (ICIs) had a more favorable safety profile for advanced liver cancer than did tyrosine kinase inhibitors (TKIs), according to a clinical trial meta-analysis.
In a pooled analysis of 30 studies, ICIs...

Source: MedPage Today Gastroenterology - July 18, 2022 Category: Gastroenterology Source Type: news